ENHANCE – Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression Trial
Eric de Groot - Imagelabonline & Cardiovascular, Eindhoven and Lunteren, the Netherlands
The Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression Trial (ENHANCE) is a two-arm clinical trial based at 18 lipid centres in eight countries (the Netherlands, Canada, South Africa, Spain, Denmark, Norway, Sweden, and USA). The principal aim of the trial was to investigate the effect of Simvastatin (80mg/day) and Ezetimibe (10mg/day) versus Simvastatin (80mg/day) and placebo on atherosclerosis in the carotid artery in individuals with heterozygous familial hypercholesterolaemia. The protocol was reviewed and approved by each participating site’s institutional review board. Informed consent was obtained during prerandomization visits.
Link to study webpage – https://clinicaltrials.gov/ct2/show/NCT00552097
Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia: Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. Am Heart J. 2005 Feb;149(2):234-9
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. N Engl J Med. 2008 Apr 3;358(14):1431-43